397 related articles for article (PubMed ID: 22423260)
1. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders.
Kelesidis T; Pothoulakis C
Therap Adv Gastroenterol; 2012 Mar; 5(2):111-25. PubMed ID: 22423260
[TBL] [Abstract][Full Text] [Related]
2. Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review.
Gopalan S; Ganapathy S; Mitra M; Neha ; Kumar Joshi D; Veligandla KC; Rathod R; Kotak BP
Cureus; 2023 Oct; 15(10):e46314. PubMed ID: 37927652
[TBL] [Abstract][Full Text] [Related]
3. Probiotic Yeast
Abid R; Waseem H; Ali J; Ghazanfar S; Muhammad Ali G; Elasbali AM; Alharethi SH
J Fungi (Basel); 2022 Apr; 8(5):. PubMed ID: 35628700
[No Abstract] [Full Text] [Related]
4. Identification and Growth Characterization of a Novel Strain of
Hossain MN; Afrin S; Humayun S; Ahmed MM; Saha BK
Front Nutr; 2020; 7():27. PubMed ID: 32309286
[TBL] [Abstract][Full Text] [Related]
5. Yeasts as probiotics: Mechanisms, outcomes, and future potential.
Sen S; Mansell TJ
Fungal Genet Biol; 2020 Apr; 137():103333. PubMed ID: 31923554
[TBL] [Abstract][Full Text] [Related]
6.
Pais P; Almeida V; Yılmaz M; Teixeira MC
J Fungi (Basel); 2020 Jun; 6(2):. PubMed ID: 32512834
[No Abstract] [Full Text] [Related]
7. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice.
Everard A; Matamoros S; Geurts L; Delzenne NM; Cani PD
mBio; 2014 Jun; 5(3):e01011-14. PubMed ID: 24917595
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of Saccharomyces boulardii in liver diseases: from passive bystander to protective performer?
Cui B; Lin L; Wang B; Liu W; Sun C
Pharmacol Res; 2022 Jan; 175():106022. PubMed ID: 34883213
[TBL] [Abstract][Full Text] [Related]
9. Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis - a review.
Moré MI; Swidsinski A
Clin Exp Gastroenterol; 2015; 8():237-55. PubMed ID: 26316791
[TBL] [Abstract][Full Text] [Related]
10. Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient.
Landaburu MF; López Daneri GA; Relloso S; Zarlenga LJ; Vinante MA; Mujica MT
Rev Argent Microbiol; 2020; 52(1):27-30. PubMed ID: 31262611
[TBL] [Abstract][Full Text] [Related]
11. [Saccharomyces boulardii CNCM I-745 influences the gut-associated immune system].
Stier H; Bischoff SC
MMW Fortschr Med; 2017 Jun; 159(Suppl 5):1-6. PubMed ID: 28643294
[TBL] [Abstract][Full Text] [Related]
12. Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases.
Kaźmierczak-Siedlecka K; Ruszkowski J; Fic M; Folwarski M; Makarewicz W
Curr Microbiol; 2020 Sep; 77(9):1987-1996. PubMed ID: 32472262
[TBL] [Abstract][Full Text] [Related]
13. Saccharomyces boulardii CNCM I-745 in different clinical conditions.
Dinleyici EC; Kara A; Ozen M; Vandenplas Y
Expert Opin Biol Ther; 2014 Nov; 14(11):1593-609. PubMed ID: 24995675
[TBL] [Abstract][Full Text] [Related]
14. Saccharomyces boulardii Administration Changes Gut Microbiota and Attenuates D-Galactosamine-Induced Liver Injury.
Yu L; Zhao XK; Cheng ML; Yang GZ; Wang B; Liu HJ; Hu YX; Zhu LL; Zhang S; Xiao ZW; Liu YM; Zhang BF; Mu M
Sci Rep; 2017 May; 7(1):1359. PubMed ID: 28465509
[TBL] [Abstract][Full Text] [Related]
15. Probiotics for the prevention of pediatric antibiotic-associated diarrhea.
Goldenberg JZ; Lytvyn L; Steurich J; Parkin P; Mahant S; Johnston BC
Cochrane Database Syst Rev; 2015 Dec; (12):CD004827. PubMed ID: 26695080
[TBL] [Abstract][Full Text] [Related]
16.
Lenka S; Singh D; Paul S; Gayen A; Chandra M
ACS Infect Dis; 2021 Apr; 7(4):733-745. PubMed ID: 33703881
[TBL] [Abstract][Full Text] [Related]
17. Probiotics for the Prevention of Pediatric Antibiotic-Associated Diarrhea.
Hayes SR; Vargas AJ
Explore (NY); 2016; 12(6):463-466. PubMed ID: 27688016
[TBL] [Abstract][Full Text] [Related]
18. [Influence of different timing of
He CX; Kong FT; Liang F; Wang KX; Li H; Liu YL; Zhao W; Zhou PP; Kong FL
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(22):1731-1734. PubMed ID: 31216821
[No Abstract] [Full Text] [Related]
19. Incidence of Saccharomyces cerevisiae fungemia in hospitalised patients administered Saccharomyces boulardii probiotic.
Wombwell E; Bransteitter B; Gillen LR
Mycoses; 2021 Dec; 64(12):1521-1526. PubMed ID: 34585799
[TBL] [Abstract][Full Text] [Related]
20. Review article: yeast as probiotics -- Saccharomyces boulardii.
Czerucka D; Piche T; Rampal P
Aliment Pharmacol Ther; 2007 Sep; 26(6):767-78. PubMed ID: 17767461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
